The use of Progentix TCP (beta-tricalciumphosphate) as a bone substitute in defects originated from curettage of benign bone tumors
Withdrawn
- Conditions
- benign bonetumorsbonecysts100059591004077610005944
- Registration Number
- NL-OMON31641
- Lead Sponsor
- Medisch Spectrum Twente
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
benign bonetumors to be treated with curettage
Exclusion Criteria
Use of Progentix TCP synthetic cancellous bone void filler is CONTRAINDICATED in the presence of one or more of the following clinical situations: Malignant bonetumors, In case of severe metabolic or systemic bone disorders that affect bone or wound healing, In case of acute and chronic infections in the operated area (soft tissue infections; inflamed, bacterial bone diseases; osteomyelitis), In case of treatment with pharmaceuticals interfering with the calcium metabolism.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>After 6 weeks, 3 months, 6 months, 1 year and 2 years, the amount of bone<br /><br>formed by creeping substitution in the bone defect will be assessed by means<br /><br>of X-rays.</p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>